Oncodesign Precision Medicine: OPM Announces Its 2022 Annual

Revenues and operating income in 2022 of €8.3 M (+110% vs. 2021 proforma), including revenues of €8 M, mainly driven by a €7 M milestone and a €0.5 M up-front Net income almost at break-even

Related Keywords

Arthur Rouill , Jan Hoflack , Karine Lignel , Philippe Genne , Mathilde Bohin Alban Dufumier , Research Tax Credit , Oncodesign Services , Transition Service Agreement , Precision Medicine , Chief Executive Officer , Oncodesign Biotechnology , Euronext Growth , Artificial Intelligence , Monday April , Ordinary General Meeting , Oncodesign Precision Medicine , Bohin Alban Dufumier , Oncodesign , Precision , Medicine , Nnounces , 022 , Nnual , Results , Rovides , Update , Linical , Developments ,